Absci Q3 revenue misses estimates, net loss widens on R&D spends
Absci Q3 revenue misses estimates, net loss widens on R&D spends
Overview
U.S. biopharma company's Q3 revenue fell and missed analyst expectations
Net loss widened in Q3 as R&D expenses rose for internal programs
Company appointed Gerry Muhle as Chief Commercial Officer to build commercial infrastructure
Outlook
Absci expects 13-week interim proof-of-concept data for ABS-201 in PHL in Dec 2026
Company anticipates full 26-week proof-of-concept data for ABS-201 in early 2027
Absci plans to initiate Phase 2 STORYLINE trial for ABS-201 in endometriosis in mid-2027
Result Drivers
R&D SPENDING - Co said higher research and development expenses were mainly due to advancement of internal programs, including direct costs for ABS-201 clinical and nonclinical development
SG&A COSTS - Selling, general, and administrative expenses rose due to increased stock-based compensation
Company press release: ID:nGNXHxDmV
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $304,000 | $727,130 (8 Analysts) |
Q3 Net Loss |
| $33.30 mln |
|
Q3 Loss Per Basic Share |
| $0.19 |
|
Q3 Operating Expenses |
| $35.30 mln |
|
Q3 Operating Income |
| -$34.99 mln |
|
Q3 Pretax Loss |
| $33.28 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Absci Corp is $15.00, about 48.2% above its November 11 closing price of $10.12
Reuters Recommended Reads
Nov 10 - Biotech firm PepGen's Q3 net loss widens as R&D expenses rise
Nov 9 - Structure Therapeutics Q3 loss widens on higher R&D costs
Nov 10 - Palisade Bio Q3 loss widens on higher R&D costs
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on AbSci
See all newsAbsci Corp reports results for the quarter ended September 30 - Earnings Summary
Brief: Absci Corp Files For Mixed Shelf Size Not Disclosed - SEC Filing
Absci Q3 revenue misses estimates, net loss widens on R&D spends
Focus: Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave